Financial Performance - Scholastic reported a quarterly loss of $2.52 per share, which was worse than the Zacks Consensus Estimate of a loss of $2.44, and compared to a loss of $2.13 per share a year ago, indicating a decline in performance [1] - The company posted revenues of $225.6 million for the quarter ended August 2025, missing the Zacks Consensus Estimate by 5.57% and down from $237.2 million year-over-year [2] - Over the last four quarters, Scholastic has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Performance and Outlook - Scholastic shares have increased approximately 27.6% since the beginning of the year, outperforming the S&P 500's gain of 12.2% [3] - The current consensus EPS estimate for the upcoming quarter is $2.05 on revenues of $552.37 million, and for the current fiscal year, it is $1.23 on revenues of $1.66 billion [7] Industry Context - The Publishing - Books industry, to which Scholastic belongs, is currently ranked in the bottom 1% of over 250 Zacks industries, indicating a challenging environment [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Scholastic's stock performance [5]

Core Viewpoint - General Mills reported quarterly earnings of $0.86 per share, exceeding the Zacks Consensus Estimate of $0.81 per share, but down from $1.07 per share a year ago [1][2] Financial Performance - The earnings surprise for the quarter was +6.17%, with the company having surpassed consensus EPS estimates in all four of the last quarters [2] - Revenues for the quarter ended August 2025 were $4.52 billion, surpassing the Zacks Consensus Estimate by 0.42%, but down from $4.85 billion year-over-year [3] Stock Performance - General Mills shares have declined approximately 22.3% since the beginning of the year, contrasting with the S&P 500's gain of 12.3% [4] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.09 on revenues of $4.81 billion, and for the current fiscal year, it is $3.65 on revenues of $18.65 billion [8] - The outlook for the industry, particularly the Food - Miscellaneous sector, is unfavorable, ranking in the bottom 30% of over 250 Zacks industries [9]

Group 1 - Evolution Petroleum reported quarterly earnings of $0.03 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, with an earnings surprise of +50.00% [1] - The company posted revenues of $21.11 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.2%, and compared to year-ago revenues of $21.23 million [2] - Over the last four quarters, Evolution Petroleum has surpassed consensus EPS estimates just once and topped consensus revenue estimates only once [2] Group 2 - The stock has added about 0.8% since the beginning of the year, underperforming the S&P 500's gain of 12.5% [3] - The current consensus EPS estimate for the coming quarter is $0.01 on $21.5 million in revenues, and $0.09 on $87.9 million in revenues for the current fiscal year [7] - The Zacks Industry Rank for Oil and Gas - Exploration and Production - United States is currently in the bottom 28% of over 250 Zacks industries, indicating potential challenges for the sector [8]

Company Overview - Monte Rosa Therapeutics (GLUE) shares increased by 44.1% to close at $6.93, with trading volume significantly higher than usual [1] - The stock has gained 5% over the past four weeks [1] Collaboration Deal - Monte Rosa entered a multi-billion-dollar collaboration with Novartis to develop therapies for immune-mediated diseases [2] - Novartis will receive an exclusive license to a discovery target developed using Monte Rosa's proprietary platform and options to license two programs from GLUE's preclinical immunology portfolio [2] Financial Terms of the Deal - Monte Rosa will receive an upfront payment of $120 million, along with option maintenance payments [3] - The total potential value of the deal is up to $5.7 billion, including royalties on future sales of the drug [3] Earnings Expectations - Monte Rosa is expected to report a quarterly loss of $0.28 per share, reflecting a year-over-year change of +3.5% [4] - Revenue is projected to be $14.07 million, up 52.6% from the same quarter last year [4] Stock Performance Insights - The consensus EPS estimate for Monte Rosa has remained unchanged over the last 30 days, indicating that stock price movements may not continue without earnings estimate revisions [5] - Monte Rosa currently holds a Zacks Rank of 3 (Hold) [5]

Core Viewpoint - Hain Celestial reported a quarterly loss of $0.02 per share, missing the Zacks Consensus Estimate of $0.04, and showing a significant decline from earnings of $0.13 per share a year ago, indicating a negative earnings surprise of -150.00% [1] Financial Performance - The company posted revenues of $363.35 million for the quarter ended June 2025, which was 3.21% below the Zacks Consensus Estimate and a decrease from $418.8 million in the same quarter last year [2] - Over the last four quarters, Hain Celestial has not surpassed consensus EPS estimates and has only topped revenue estimates once [2] Stock Performance - Hain Celestial shares have declined approximately 65% since the beginning of the year, contrasting with a 12% gain in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $373.22 million, while for the current fiscal year, the estimate is $0.23 on revenues of $1.53 billion [7] Industry Outlook - The Zacks Industry Rank for Food - Miscellaneous, which includes Hain Celestial, is currently in the bottom 35% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Hain Celestial's stock performance [5]

RF Industries, Ltd. (RFIL) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +66.67%. A quarter ago, it was expected that this company would post earnings of $0.04 per share when it actually produced earnings of $0.07, delivering a surprise of +75%.Over the last four quarters, the company ...

Core Insights - Vera Bradley reported a quarterly loss of $0.02 per share, outperforming the Zacks Consensus Estimate of a loss of $0.15, marking an earnings surprise of +86.67% [1] - The company generated revenues of $70.86 million for the quarter ended July 2025, missing the Zacks Consensus Estimate by 9.76% and down from $110.82 million year-over-year [2] - The stock has underperformed, losing about 42% since the beginning of the year compared to the S&P 500's gain of 11.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $63.95 million, and for the current fiscal year, it is -$0.63 on revenues of $275.2 million [7] - The estimate revisions trend for Vera Bradley was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Retail - Apparel and Shoes industry, to which Vera Bradley belongs, is currently in the bottom 40% of the Zacks Industry Rank, which may negatively impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that investors should monitor these revisions closely [5]

Core Molding Technologies, Inc. (CMT)  shares ended the last trading session 8.2% higher at $20.98. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 13.1% gain over the past four weeks.Core Molding’s rally is largely driven by optimism over rising customer demand for molded thermoplastic and thermoset products in the industrial and utilities markets. Also, new program wins across diverse markets including constructi ...

Core Viewpoint - Lovesac reported a quarterly loss of $0.45 per share, which was better than the Zacks Consensus Estimate of a loss of $0.72, indicating a positive earnings surprise of +37.50% [1] - The company has shown mixed performance in revenue, with $160.53 million reported for the quarter, slightly missing the consensus estimate by 0.2% [2] Financial Performance - The loss per share of $0.45 compares to a loss of $0.38 per share a year ago, indicating a deterioration in year-over-year performance [1] - Over the last four quarters, Lovesac has surpassed consensus EPS estimates four times and topped revenue estimates two times [2] Stock Performance - Lovesac shares have declined approximately 12.3% since the beginning of the year, contrasting with the S&P 500's gain of 11.1% [3] - The current Zacks Rank for Lovesac is 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is -$0.27 on revenues of $154.51 million, while for the current fiscal year, it is $0.90 on revenues of $706.8 million [7] - The trend of earnings estimate revisions is mixed ahead of the earnings release, which could influence future stock performance [6] Industry Context - The Retail - Home Furnishings industry, to which Lovesac belongs, is currently ranked in the bottom 15% of over 250 Zacks industries, which may negatively impact stock performance [8]

KalVista Pharmaceuticals, Inc. (KALV) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to a loss of $0.87 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -23.08%. A quarter ago, it was expected that this company would post a loss of $0.77 per share when it actually produced a loss of $0.99, delivering a surprise of -28.57%.Over the last four quarters, the c ...